Proposal for OLT1177 (Dapansutrile; InvivoGen, catalog #tlrl-olt1177)

Overview of Therapeutic Candidate:
OLT1177, also known as dapansutrile, is a synthetic small-molecule inhibitor that belongs to the β-sulfonyl nitrile class of compounds, developed specifically for its selective inhibition of the NLRP3 inflammasome. The compound was synthesized via a chemically directed approach—in particular, its synthesis involved an alkylation reaction of sodium methanesulfinate with 3-bromopropionitrile, yielding a β-sulfonyl nitrile moiety that confers its inhibitory activity (Marchetti et al., 2018). This class of small molecule inhibitors has been widely explored for targeting inflammatory pathways through modulation of innate immune responses. Historically, β-sulfonyl nitrile compounds have attracted attention as therapeutic agents due to their capacity to engage key protein domains involved in inflammation while maintaining selectivity and oral bioavailability, attributes that are critical for chronic treatment regimens (Marchetti et al., 2018).

Therapeutic History:
OLT1177 has progressed through several stages of development and clinical evaluation in diseases characterized by uncontrolled inflammation, notably in acute gout flares, heart failure, and conditions linked to cytokine release syndromes. In Phase I clinical trials, dapansutrile demonstrated an excellent safety profile when administered to healthy subjects at dosages up to 1000 mg per day for 8 days, thereby establishing its tolerability and preliminary evidence of target engagement (Jansen et al., 2019). Moreover, therapeutic evaluations in inflammatory settings—such as a randomized, double-blind, dose-escalation study in patients with NYHA II–III systolic heart failure—further underscored its favorable safety profile and pharmacodynamic effects despite the fact that current clinical investigations have not directly targeted Chronic Kidney Disease (CKD) populations (ClinicalTrials.gov, n.d.). Preclinical studies in animal models of crystal nephropathy and diabetic nephropathy have demonstrated that treatment with OLT1177 leads to significant reductions in renal IL-1β levels, decreased macrophage infiltration, and attenuated fibrogenesis, suggesting that its benefits extend to kidney-related inflammatory damage (Mulay, 2019). Although clinical trials specifically focused on CKD or renal inflammation are lacking at this point, the robust anti-inflammatory effects observed in related models and conditions provide a sound rationale for repurposing OLT1177 in chronic kidney disease.

Mechanism of Action:
At the molecular level, OLT1177 selectively inhibits the NLRP3 inflammasome by targeting its central NACHT domain, where it interferes with ATPase activity that is critical for the oligomerization process necessary for inflammasome assembly. Under normal conditions, activation of the NLRP3 inflammasome triggers the recruitment of the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD), leading to the formation of a multi-protein complex that activates caspase-1 and drives the processing of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and interleukin-18 (IL-18) (Kim et al., 2019). OLT1177 binds specifically to the NACHT domain of NLRP3, thereby blocking the interaction between NLRP3 and ASC, which is a necessary event for full inflammasome assembly (Marchetti et al., 2018). In doing so, it prevents the proteolytic cleavage of caspase-1 and effectively reduces the secretion of IL-1β. This mechanism is particularly significant in environments of hyperglycemic stress, where increased NLRP3 activity in renal tubular epithelial cells (TECs) drives inflammation, pyroptotic cell death, and subsequent tubulointerstitial fibrosis (Mulay, 2019). Additionally, by curtailing downstream cytokine release and pyroptosis, OLT1177 is believed to mitigate the metabolic cost of inflammation, an effect that has been observed in multiple preclinical in vivo studies in conditions ranging from acute arthritis to cardiac dysfunction (Jansen et al., 2019; Schwaid & Spencer, 2020).

Expected Effect:
The central hypothesis is that through selective inhibition of the NLRP3 inflammasome, OLT1177 will effectively block the recruitment of ASC and disrupt subsequent caspase-1 activation in renal tubular cells, particularly under conditions of hyperglycemia which are common in diabetic nephropathy. Under hyperglycemic stress, renal tubular epithelial cells exhibit increased reactive oxygen species (ROS) generation and aberrant inflammasome activation resulting in heightened secretion of IL-1β, a cytokine implicated in promoting fibroblast activation and extracellular matrix deposition. By preventing the cleavage of pro-IL-1β into its active form, OLT1177 is expected to prevent pyroptotic cell death of TECs and interrupt the deleterious cycle of inflammation-driven fibrogenesis in the kidney (Kim et al., 2019; Mulay, 2019). Evidence from animal models indicates that selective blockade of the NLRP3 inflammasome leads to a marked decrease in renal inflammation as evidenced by reduced macrophage infiltration and lower profibrotic cytokine levels, which supports the expectation that OLT1177 could yield appreciable renoprotective outcomes in CKD (ClinicalTrials.gov, n.d.). In the proposed assay, it is anticipated that OLT1177 will reduce markers of inflammation such as IL-1β and IL-18 in the culture medium of hyperglycemia-stressed TECs, thereby correlating with decreased pyroptosis and improved cell viability. This would be further corroborated by downstream effects such as reduced activation of profibrotic pathways, including lower TGF-β signaling and diminished deposition of fibrotic markers, ultimately mitigating the progression toward renal fibrosis (Cliff, 2023; Mulay, 2019).

Overall Evaluation:
In summary, OLT1177 (dapansutrile) emerges as a promising therapeutic candidate with substantial potential for repurposing in the treatment of Chronic Kidney Disease owing to its well-characterized mechanism of action, favorable preclinical results, and established safety profile in early clinical studies. One of the major strengths of OLT1177 lies in its selective inhibition of the NLRP3 inflammasome, an attractive target given the critical role of NLRP3 in mediating renal inflammation, pyroptosis, and subsequent fibrogenesis. Its synthetic origins and robust medicinal chemistry underpin its precise targeting of the NACHT domain in NLRP3, effectively sparing other inflammasomes and reducing the risk of broad immunosuppression (Marchetti et al., 2018; Kim et al., 2019). Furthermore, its oral bioavailability and metabolic stability make it suitable for chronic administration, an essential consideration for CKD where long-term therapy is required (ClinicalTrials.gov, n.d.).

From a therapeutic history perspective, although OLT1177 has not yet been directly tested in human CKD patient populations, its successful progression through Phase I trials for conditions such as gout and heart failure, combined with promising data in animal models of crystal nephropathy and diabetic nephropathy, strongly supports its potential utility in renal settings (Jansen et al., 2019; Mulay, 2019). Preclinical studies show reduced renal IL-1β secretion, diminished macrophage infiltration, and attenuated fibrogenesis when NLRP3 is inhibited by agents like OLT1177, lending biological credence to the hypothesis that inflammasome inhibition could slow CKD progression (ClinicalTrials.gov, n.d.).

At the molecular level, the precise action of OLT1177—binding to the NACHT domain of NLRP3 and preventing ASC recruitment—represents a highly targeted approach that contrasts with cytokine-neutralizing therapies such as anti-IL-1β antibodies. This specificity is advantageous because it not only prevents the generation of IL-1β but also curtails the activation of NFκB and other downstream inflammatory cascades, potentially reducing off-target effects and preserving broader immune competence (Marchetti et al., 2018; Schwaid & Spencer, 2020). Additionally, the expected anti-inflammatory effects in renal tubular cells—specifically preventing pyroptosis and fibrogenesis—are consistent with literature demonstrating that NLRP3 is upregulated in tubular epithelial cells under hyperglycemic and inflammatory stress (Kim et al., 2019; Mulay, 2019).

However, several challenges remain. One of the limitations stems from the current lack of direct clinical evidence in CKD populations; while animal models provide a strong rationale, the translation of these findings into human CKD may be complicated by the multifactorial nature of the disease, where multiple pathways contribute to renal injury beyond inflammasome activation. Additionally, the chronic nature of CKD necessitates prolonged administration of therapeutic agents, and long-term safety data for OLT1177 in such a setting are still pending. There is also the possibility that inhibiting the NLRP3 inflammasome might impair necessary innate immune responses, although the specificity of OLT1177 for the NLRP3 complex—in contrast to more generalized anti-inflammatory agents—should, in theory, mitigate this concern (Seok et al., 2021).

Moreover, while the preclinical data in models of diabetic nephropathy and crystal-induced kidney injury are promising, variability in genetic and environmental factors in human CKD could affect the compound’s efficacy. It will therefore be critical to design dedicated clinical trials in defined CKD populations, ideally incorporating biomarkers of inflammasome activity, such as circulating IL-1β and IL-18 levels, as well as imaging and functional assessments of renal fibrosis and function. The anti-fibrotic effects, in particular, warrant closer mechanistic studies to confirm that inhibition of TEC pyroptosis and preservation of tubular integrity occur in the human kidney as they do in animal models (Williams et al., 2022; Cliff, 2023).

In conclusion, OLT1177 (dapansutrile) represents a compelling candidate for repurposing in Chronic Kidney Disease due to its targeted mechanism of action, favorable pharmacological profile, and preclinical evidence supporting its renoprotective effects. Its ability to directly inhibit the assembly of the NLRP3 inflammasome by binding to the NACHT domain and blocking ASC recruitment addresses a critical upstream event in the inflammatory cascade that leads to caspase-1 activation, IL-1β secretion, and subsequent pyroptosis of renal tubular cells. This mode of action has the potential to attenuate the inflammation-driven fibrogenesis that is central to CKD progression, particularly in diabetic nephropathy where hyperglycemic stress is a key driver of renal injury.

Strengths of OLT1177 include its synthetic origin allowing for structural optimization, its demonstrated safety in Phase I clinical trials, its oral bioavailability which is advantageous for chronic therapy, and its selective inhibitory action that minimizes off-target effects. Additionally, existing preclinical studies showing reduced renal IL-1β, diminished macrophage infiltration, and lowered fibrotic responses in models of nephropathy provide a promising foundation for further exploration in CKD (Mulay, 2019; Jansen et al., 2019).

Weaknesses or challenges include the current absence of dedicated clinical trials in CKD, the complexity of CKD pathophysiology where multiple inflammatory and fibrotic pathways are involved, and the potential risk that chronic inhibition of the NLRP3 inflammasome could in some contexts compromise the host defense or alter essential cellular processes. These concerns underscore the need for carefully designed preclinical studies specifically in renal disease models, followed by early phase clinical trials in well-defined CKD populations to evaluate therapeutic efficacy and long-term safety.

Overall, based on the comprehensive literature review, the mechanistic rationale, and the encouraging preclinical and early clinical data available, OLT1177 shows significant potential as a repurposed therapeutic candidate for Chronic Kidney Disease. The next steps should involve further detailed studies in CKD-specific preclinical models that assess not only inflammatory cytokine modulation but also functional outcomes such as glomerular filtration rate, proteinuria reduction, and fibrosis attenuation. A robust clinical development program targeting patients with diabetic nephropathy and other forms of CKD characterized by inflammasome activation would be the logical progression to validate its clinical utility (Marchetti et al., 2018; Jansen et al., 2019; Mulay, 2019).

References
Cliff, C. L. (2023). Understanding the role of connexin 43 hemichannel activity in mediating tubulointerstitial inflammation and fibrosis in models of diabetic nephropathy. Unknown Journal.
ClinicalTrials.gov. (n.d.). Clinical trial search for dapansutrile OR OLT1177 OR NLRP3 inhibitor AND (chronic kidney disease OR nephropathy OR renal inflammation) [Search query]. Retrieved from https://clinicaltrials.gov
Jansen, T., Klück, V., Janssen, M., Comarniceanu, A., Efde, M., Scribner, C., Barrow, R., Skouras, D., Dinarello, C., & Joosten, L. (2019). P160 the first phase 2a proof-of-concept study of a selective NLRP3 inflammasome inhibitor, Dapansutrile™ (OLT1177™), in acute gout. Annals of the Rheumatic Diseases, 78, A70–A71. https://doi.org/10.1136/annrheumdis-2018-ewrr2019.142
Kim, Y. G., Kim, S.-M., Kim, K.-P., Lee, S.-H., & Moon, J.-Y. (2019). The role of inflammasome-dependent and inflammasome-independent NLRP3 in the kidney. Cells, 8(11), 1389. https://doi.org/10.3390/cells8111389
Marchetti, C., Swartzwelter, B., Gamboni, F., Neff, C. P., Richter, K., Azam, T., Carta, S., Tengesdal, I., Nemkov, T., D’Alessandro, A., Henry, C., Jones, G. S., Goodrich, S. A., St. Laurent, J. P., Jones, T. M., Scribner, C. L., Barrow, R. B., Altman, R. D., Skouras, D. B., Gattorno, M., Grau, V., Janciauskiene, S., Rubartelli, A., Joosten, L. A. B., & Dinarello, C. A. (2018). OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proceedings of the National Academy of Sciences of the United States of America, 115(7), E1530–E1539. https://doi.org/10.1073/pnas.1716095115
Mulay, S. R. (2019). Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases. Kidney International, 96(1), 58–66. https://doi.org/10.1016/j.kint.2019.01.014
Schwaid, A. G., & Spencer, K. B. (2020). Strategies for targeting the NLRP3 inflammasome in the clinical and preclinical space. Journal of Medicinal Chemistry, 64(1), 101–122. https://doi.org/10.1021/acs.jmedchem.0c01307
Seok, J. K., Kang, H. C., Cho, Y.-Y., Lee, H. S., & Lee, J. Y. (2021). Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases. Archives of Pharmacal Research, 44(1), 16–35. https://doi.org/10.1007/s12272-021-01307-9
Williams, B. M., Cliff, C. L., Lee, K., Squires, P. E., & Hills, C. E. (2022). The role of the NLRP3 inflammasome in mediating glomerular and tubular injury in diabetic nephropathy. Frontiers in Physiology, 13, 907504. https://doi.org/10.3389/fphys.2022.907504
